

Title (en)

COMBINATION IMMUNOTHERAPY OF IL-15 AND CD40 AGONIST IN CANCER TREATMENT

Title (de)

KOMBINATIONSIMMUNOTHERAPIE VON IL-15- UND CD40-AGONISTEN IN DER KREBSBEHANDLUNG

Title (fr)

IMMUNOTHÉRAPIE COMBINÉE D'AGONISTES IL-15 ET CD40 DANS LE TRAITEMENT DU CANCER

Publication

**EP 4069739 A1 20221012 (EN)**

Application

**EP 20824142 A 20201204**

Priority

- EP 19214049 A 20191206
- EP 2020084665 W 20201204

Abstract (en)

[origin: WO2021110930A1] The present invention relates to the field of combination immunotherapy, more in particular to a combination comprising IL-15 and a CD40 agonist for use in the treatment of cancer, such as and not limited to, pancreatic cancer (e.g. pancreatic ductal adenocarcinoma and pancreatic neuro-endocrine tumours).

IPC 8 full level

**C07K 16/28** (2006.01); **A61K 38/20** (2006.01); **A61K 39/395** (2006.01)

CPC (source: EP IL US)

**A61K 38/2086** (2013.01 - EP IL US); **A61K 39/3955** (2013.01 - EP IL); **C07K 16/2878** (2013.01 - EP IL US); **A61K 2039/505** (2013.01 - EP IL US); **A61K 2039/545** (2013.01 - EP IL US); **A61K 2300/00** (2013.01 - IL)

C-Set (source: EP)

1. **A61K 39/3955 + A61K 2300/00**
2. **A61K 38/2086 + A61K 2300/00**

Citation (search report)

See references of WO 2021110930A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

**WO 2021110930 A1 20210610**; AU 2020395907 A1 20220721; CA 3163777 A1 20210610; CN 115052891 A 20220913; EP 4069739 A1 20221012; IL 293613 A 20220801; JP 2023505303 A 20230208; US 2022411524 A1 20221229

DOCDB simple family (application)

**EP 2020084665 W 20201204**; AU 2020395907 A 20201204; CA 3163777 A 20201204; CN 202080092819 A 20201204; EP 20824142 A 20201204; IL 29361322 A 20220606; JP 2022534242 A 20201204; US 202017781583 A 20201204